多器官功能障碍综合征患者CD14+单核细胞人类白细胞DR抗原的表达

目的探讨多器官功能障碍综合征(MODS)患者的免疫状态与患者预后的关系.方法21例均符合MODS诊断标准,用流式细胞仪测定不同时段单核细胞CD14+人类白细胞DR抗原(HLA-DR)的百分比.结果MODS患者cD14+单核细胞HLA-DR含量均低于30%,死亡组入院后CD14+单核细胞HLA-DR呈进行性降低,与存活组相比有显著意义(P＜0.05),且入院后1 hCD14+单核细胞HLA-DR＜10%的患者均死亡.结论MODS患者的免疫状态低下,动态监测CD14+单核细胞HLA-DR的变化对患者的预后有明确的指导意义.

Clinical Trial to Verify the Value of CD14 + Monocyte Human Leukocyte Antigen DR in Patients with Multiple Organ Dysfunction Syndrome

Objective To investigate the changes in the percentage of CD monocyte expressing human leukocyte antigen(HLA-DR) and for making prediction of prognosis in patients with multiple organ dysfunction syndrome(MODS).Methods Patients with MODS were set forth by ACCP/SCCM enrolled in this clinical trial. Flow cytometry application was employed to measure the levels of HLA-DR in various period of MODS.Results Totally, 21patients were enrolled in this study. The level of HLA-DR in all patients was lower than 30%, and in the patients who died of it dropped grogressively. Significant difference was found between the survivors group and death group. Conclusion It is reconfirmed that the CD monocyte HLA-DR can be a reliable and valuable index to judge immunosuppression and serve as an index to predict the outcome in MODS patient.